#1 Clinical Trials Search in Europe

Adeno-Associated Viral Vector Serotype 2.7M8 Containing The Chrimsonr-Tdtomato Gene

This article discusses ongoing clinical trials investigating the use of a novel gene therapy, GS030-DP, for treating Retinitis Pigmentosa. The therapy utilizes an Adeno-Associated Viral Vector Serotype 2.7M8 containing the ChrimsonR-tdTomato gene. These trials aim to evaluate the safety, tolerability, and potential effectiveness of this innovative approach in patients with non-syndromic Retinitis Pigmentosa, a genetic eye disorder causing progressive vision loss.

Table of Contents

What is GS030?

GS030 is an innovative gene therapy being developed to treat a condition called retinitis pigmentosa. It consists of two main components[1]:

  1. GS030-DP: This is the actual gene therapy product, which is a suspension for injection.
  2. GS030-MD: This is a medical device used in conjunction with the gene therapy.

The active substance in GS030-DP is called adeno-associated viral vector serotype 2.7m8 containing the ChrimsonR-tdTomato gene. This is also sometimes referred to as rAAV2.7m8-CAG-ChrimsonR-tdTomato[1].

How Does GS030 Work?

GS030 works through a process called optogenetics. Here’s a simplified explanation of how it functions[1]:

  1. The gene therapy (GS030-DP) is injected into the eye through a procedure called intravitreal injection. This means it’s injected directly into the vitreous, the gel-like substance in the eye.
  2. The therapy delivers a gene that produces a light-sensitive protein (ChrimsonR-tdTomato) in certain cells of the retina.
  3. These cells, which were not previously light-sensitive, can now respond to light.
  4. The patient then uses special goggles (GS030-MD) that convert visual information into light pulses at a specific wavelength.
  5. These light pulses stimulate the newly light-sensitive cells in the retina, potentially allowing the patient to perceive visual information.

What is Retinitis Pigmentosa?

Retinitis pigmentosa is a group of rare genetic disorders that involve a breakdown and loss of cells in the retina. The retina is the light-sensitive tissue that lines the back of the eye. People with this condition have progressive vision loss, often leading to blindness[1].

Clinical Trial Details

The clinical trial for GS030 is a Phase 1/2a study, which means it’s an early-stage trial primarily focused on safety and determining the right dose. Here are some key details[1]:

  • The main goal is to evaluate the safety and tolerability of GS030.
  • The study will use increasing doses of GS030-DP, administered through a single intravitreal injection.
  • Participants will use the GS030-MD device for repeated light stimulation.
  • The trial will also look at how well the treatment works, measuring things like visual acuity (sharpness of vision), visual function, and quality of life.

Potential Benefits

If successful, GS030 could potentially[1]:

  • Improve visual acuity (the ability to see detail)
  • Enhance visual function and field of vision
  • Improve orientation and mobility
  • Increase quality of life for people with retinitis pigmentosa

However, it’s important to note that as this is an early-stage trial, the effectiveness of the treatment is still being evaluated.

Safety Considerations

As with any medical treatment, there are potential risks and side effects to consider. The trial is designed to carefully monitor for any adverse events related to[1]:

  • The intravitreal injection of GS030-DP
  • The repeated use of the GS030-MD device
  • Potential immune responses to the viral vector or the ChrimsonR-tdTomato protein

Eligibility for the Trial

The trial has specific criteria for who can participate. Some key points include[1]:

  • Participants must be between 18 and 75 years old
  • They must have a diagnosis of non-syndromic retinitis pigmentosa
  • Their visual acuity must be no better than light perception in the dose-escalation part of the trial
  • They must be able to use and follow instructions for the GS030-MD device

There are also several exclusion criteria, such as prior gene therapy, certain eye conditions, or other health issues that might interfere with the study.

Conclusion

GS030 represents a promising new approach to treating retinitis pigmentosa, a condition that currently has no cure. By using gene therapy and optogenetics, it aims to restore some level of visual function to people with this condition. However, as with all experimental treatments, more research is needed to fully understand its effectiveness and safety. The ongoing clinical trial will provide crucial information about this innovative therapy.

Aspect Details
Study Type Phase 1/2a, open-label, non-randomized, dose-escalation study
Condition Non-syndromic Retinitis Pigmentosa
Intervention GS030-DP (gene therapy) via intravitreal injection + GS030-MD (light stimulation device)
Primary Objective Evaluate safety and tolerability of escalating doses of GS030-DP
Secondary Objectives Assess treatment effect on vision, ocular measures, and quality of life
Key Inclusion Criteria Adults 18-75 years, diagnosis of non-syndromic RP, severely impaired vision
Key Exclusion Criteria Prior gene therapy, significant recent eye surgery, certain eye conditions
Primary Endpoint Safety and tolerability at Week 52/Year 1
Secondary Endpoints Changes in visual function, structural changes in the eye, quality of life, immune responses

FAQ

  • What is the purpose of the clinical trial using GS030-DP? The main purpose of this clinical trial is to evaluate the safety and tolerability of GS030-DP, a gene therapy administered via a single intravitreal injection, along with repeated light stimulation using a device called GS030-MD in patients with non-syndromic Retinitis Pigmentosa.
  • Who is eligible to participate in this clinical trial? Eligible participants are adults aged 18 to 75 years with a diagnosis of non-syndromic Retinitis Pigmentosa. They must have severely impaired vision (no better than light perception in the dose-escalation cohorts) and a relatively preserved ganglion cell layer and retinal nerve fiber layer.
  • How is the gene therapy administered? The gene therapy, GS030-DP, is administered through a single intravitreal injection. This means the medication is injected directly into the vitreous, the clear gel-like substance in the eye.
  • What are the main things being measured in this trial? The trial primarily measures the safety and tolerability of GS030 treatment at Week 52/Year 1. It also assesses changes in visual function, structural changes in the eye, quality of life, and immune responses to the therapy components.
  • Are there any specific exclusions for participating in this trial? Yes, there are several exclusions. Some key ones include prior gene therapy, significant recent eye surgery, certain eye conditions that interfere with assessments, active eye inflammation, and pregnancy. Participants also cannot be taking certain photosensitizing drugs or immunosuppressive therapies.

Ongoing Clinical Trials on Adeno-Associated Viral Vector Serotype 2.7M8 Containing The Chrimsonr-Tdtomato Gene

  • Study of GS030 gene therapy safety and tolerability in patients with Retinitis Pigmentosa

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Retinitis Pigmentosa: A group of rare, genetic disorders that involve a breakdown and loss of cells in the retina – the light-sensitive tissue that lines the back of the eye. It typically leads to progressive vision loss.
  • Gene Therapy: A technique that uses genes to treat or prevent disease. In this case, it involves introducing genetic material into cells to compensate for abnormal genes or to make a beneficial protein.
  • Adeno-Associated Viral Vector: A tool used in gene therapy to deliver genetic material into cells. It's derived from a virus but modified to be safe and non-infectious.
  • Intravitreal Injection: A procedure where medication is injected directly into the vitreous cavity in the eye. The vitreous is the clear, gel-like substance that fills the eye behind the lens.
  • ChrimsonR-tdTomato Gene: A specific gene used in this therapy that encodes for light-sensitive proteins, potentially allowing cells in the retina to respond to light stimulation.
  • Ganglion Cell Layer: A layer of the retina containing nerve cells that process visual information and transmit it to the brain.
  • Retinal Nerve Fiber Layer: The inner layer of the retina, composed of the axons of ganglion cells, which carry visual information from the eye to the brain.
  • Optical Coherence Tomography (OCT): A non-invasive imaging test that uses light waves to take cross-section pictures of the retina, allowing doctors to see each of the retina's distinctive layers.
  • Visual Acuity: A measure of the sharpness or clarity of vision, typically tested using an eye chart.
  • Fundus: The interior surface of the eye, including the retina, optic disc, and blood vessels, which can be seen through an ophthalmoscope.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-of-gs030-dp-gene-therapy-for-patients-with-retinitis-pigmentosa/